Proteomic identification of 14‐3‐3ϵ as a linker protein between pERK1/2 inhibition and BIM upregulation in human osteosarcoma cells
Kim KO, Hsu AC, Lee HG, Patel N, Chandhanayingyong C, Hickernell T, Lee F. Proteomic identification of 14‐3‐3ϵ as a linker protein between pERK1/2 inhibition and BIM upregulation in human osteosarcoma cells. Journal Of Orthopaedic Research® 2014, 32: 848-854. PMID: 24536031, DOI: 10.1002/jor.22598.Peer-Reviewed Original ResearchConceptsPERK1/2 inhibitionHuman osteosarcoma cellsBim expressionSubset of patientsOsteosarcoma cellsConventional cytotoxic agentsConventional cytotoxic treatmentAnti-cancer effectsInhibition of pERK1/2Pro-apoptotic mechanismsMultifocal osteosarcomaMultimodality chemotherapyCytotoxic treatmentUpregulation of BimOsteosarcoma treatmentOsteosarcoma cell deathCytotoxic agentsExpression of BimPotential mediatorsTreatment of PD98059UpregulationTreatmentPD98059 treatmentInhibitionCell deathSystemic Therapy in Patients with Resectable and Unresectable Cases of Giant Cell Tumor: A Systematic Review
Kaiser P, Compton J, Caldwell J, Hickernell T, Lee F. Systemic Therapy in Patients with Resectable and Unresectable Cases of Giant Cell Tumor: A Systematic Review. Journal Of Cancer Therapy 2014, 2014: 339-353. DOI: 10.4236/jct.2014.54041.Peer-Reviewed Original ResearchGiant cell tumorAnti-osteoclastic agentsSystemic bisphosphonatesSystemic treatmentResectable tumorsUnresectable casesRecurrence rateCell tumorsSide effectsCases of GCTMetastatic giant cell tumorUnresectable giant cell tumorPrimary giant cell tumorSevere side effect profileStabilization of diseaseOverall recurrence rateRetrospective case seriesSide effect profileSubset of patientsHigh-level evidenceSeries of patientsLow recurrence ratePrimary bone tumorsStandard of careCommon benign tumor